Financial Performance - Net revenues increased by 2.3% year-over-year, reaching $2.236 billion[4] - Adjusted EBITDAR increased by 6.3% year-over-year[7] - Adjusted EBITDAR margin increased by 100 bps[7] - Las Vegas net revenues increased by 6.9% year-over-year, reaching $973 million[10] - Las Vegas Adjusted EBITDAR increased by 16.0% year-over-year, reaching $356 million[10] - Other U S net revenues decreased by 0.5% year-over-year, to $1.119 billion[10] - All Other net revenues decreased by 4.0% year-over-year, to $144 million[10] Key Performance Indicators - Customer Service Scores increased by 2.65%[7] - Net Promoter Score increased by 4.02%[7] - Las Vegas Occupancy increased by 290 bps[9] - Las Vegas ADR increased by 3.7%[9] - Las Vegas RevPAR increased by 7.0%[9] Efficiency - Labor efficiency improved by 20 bps[2] - Marketing efficiency improved by 60 bps[3] Merger - Merger with Eldorado Resorts expected to close in 1H 2020[8]

Financial Performance - Q4 2019 - Net revenues increased by 2.6% year-over-year[3], reaching $2169 million[8] - Adjusted EBITDAR increased by 3.4% year-over-year[3], with a margin of 27.0%, up 20 bps[3] - Las Vegas net revenue increased by 4.2% year-over-year[3], reaching $989 million[8] - Las Vegas adjusted EBITDAR increased by 3.4% year-over-year[3], reaching $363 million[8] - Adjusted EBITDAR excluding Rio increased by 4.5% year-over-year[3] Financial Performance - Full Year 2019 - Net revenues increased by 4.2% year-over-year[3], reaching $8742 million[16] - Adjusted EBITDAR increased by 4.7% year-over-year[3], with a margin of 27.6%, up 10 bps[3], reaching $2417 million[17] - Marketing efficiency improved to 20.0%, up 10 bps[3] - Labor efficiency improved to 23.4%, up 30 bps[3] Las Vegas Key Performance Indicators - Las Vegas RevPAR increased by 2.1% year-over-year[3] - Las Vegas Adjusted EBITDAR Margin was 36.7%[10]

Financial Performance - Q1 2020 - Net revenues for Caesars Entertainment were $1828 million, a decrease of $287 million or 136% year-over-year [6] - Adjusted EBITDAR was $302 million, a decrease of $260 million or 463% year-over-year [6] - Las Vegas net revenue was $822 million, down $133 million or 139% year-over-year [6] - Other U S net revenue was $874 million, down $136 million or 135% year-over-year [6] - All Other net revenue was $132 million, down $18 million or 120% year-over-year [6] Impact of COVID-19 - Temporary property closures began in March, impacting financial results [1] - Aggressive cost management was implemented to preserve liquidity [1] - The company provided two weeks of closure pay and continued medical benefits for employees [3] Liquidity and Debt - Cash and cash equivalents totaled $2677 million as of March 31, 2020 [14] - Total financial debt (excluding convertible debt) was $8700 million [14] - Maintenance Capex was $109 million [15]

Company Overview - Shattuck Labs is a clinical-stage biotechnology company focused on bi-functional fusion proteins [10] - The company has $114.6 million in cash and cash equivalents and investments as of March 31, 2024, expected to fund operations into 2026 [10] SL-172154 Clinical Trials (AML/HR-MDS) - In a Phase 1A/B trial, 14 frontline TP53m AML patients were enrolled [77] - In the same trial, 22 frontline HR-MDS patients were enrolled [77] - In TP53m AML patients, 3 out of 11 evaluable patients achieved a CR/CRi [54] - In HR-MDS patients, 9 out of 14 evaluable patients achieved a CR/mCR [70] - 81% of HR-MDS patients in the trial had TP53 mutation or deletion [65] SL-172154 Clinical Trials (PROC) - Enrollment was completed in Q4'23 in the Phase 1B dose expansion cohort for PROC [110] - Initial data showed a 27% Objective Response Rate (ORR) for SL-172154 in combination with PLD [110] - 50% of PROC patients had received one prior line of systemic therapy, and 50% had received two or more [106]

Company Overview - Precision Optics (POCI) is a vertically integrated optics company focused on micro-optics and imaging technologies for the healthcare and defense/aerospace industries[7] - The company's business model involves close collaboration with medical device and defense companies from the early design stages through manufacturing[13, 14] - The company has launched Unity CMOS Imaging Platform to drive growth in development pipeline[11] Financial Performance - The company's revenue has grown from $3.9 million in 2016 to $19.1 million in 2024[51] - The company's gross margin was 30.3% in 2024[54] - The company's adjusted EBITDA was -$1.55 million in 2024[57] Recent Orders and Backlog - The company announced a $9 million production order in May 2024 for a single-use cystoscopy program[47] - The company has minimum purchase commitments of nearly $4 million per year through calendar year 2026 for a top tier aerospace program[47] - The company's current customer program backlog is $6.6 million, expected to be delivered over the next 12 months (as of April 2025)[47] Growth Strategy - The company aims to continue and expand production lines for record backlog, especially for two recent large programs[48] - The company intends to advance pipeline projects to commercialization and expand the pipeline with new development programs leveraging the Unity Platform[48]

Company Overview - Loop Industries has developed a patented technology to produce virgin-quality polyester from 100% recycled content[10] - The technology depolymerizes waste PET into DMT and MEG monomers, which are then purified and recombined[11] - Loop's technology reduces GHG emissions by up to 81% compared to traditional polyester production[12] - The company has been operating a production facility in Canada for 5 years[28] Commercialization Strategy - Loop will deploy its technology through direct investment and licensing[28] - The company sold its first technology license to Reed Societe Generale Group in December 2024[28] - Loop generates revenue through royalties, engineering services, and sales of plant modules[66, 69] - Loop has a 50/50 joint venture with Ester Industries to build a 70kta commercial facility in India, expected to be operational in 2027[72, 73] Market Opportunity - Humankind has produced 83 billion tonnes of plastics since the 1950s[6] - 49 billion tonnes of plastic (60%) have been disposed of in landfills or the environment[6] - Approximately 25 million tonnes of plastic textiles are landfilled or incinerated annually[6] - Estimated Global Demand for PET Tire cord is 518 KTA[115]

Strategy and Performance - Phillips 66's TSR outperformed its synthetic proxy peer median by 22% (67% vs 45%) since the 2022 CEO transition[18] - The company's integrated model results in a 39% higher return of capital to shareholders compared to its weighted proxy peer average over the last 10 years (646% vs 465%)[20, 21] - Phillips 66's average return on capital employed is 44% higher than its weighted proxy peer average over the last 10 years (107% vs 74%)[22, 23] - The company has a 15% compound annual growth rate (CAGR) in dividends[32, 36] - Phillips 66 has repurchased 35% of its initial shares outstanding since the 2012 spin-off[36] Refining - Phillips 66 aims to reduce refining costs to $550 per barrel by 2027[51] - The company reduced refining costs from $698 per barrel to $590 per barrel[50] - Every $050 per barrel of cost reduction is expected to improve adjusted EBITDA by approximately $315 million[66] Midstream - Phillips 66 projects Midstream adjusted EBITDA growth since 2021[78] - The company is projecting $975 million in Midstream capital spend in 2025[90] Chemicals - CPChem is expected to add approximately 7 million metric tons per annum (MMTA) of capacity through self-funded organic growth from 2017 to 2027[101, 143] - CPChem anticipates a 19% chain margin recovery by 2027[143] Synergies and Capital Allocation - Phillips 66 generates over $500 million in annual operating synergies through integration[106] - The company targets returning over 50% of net operating cash flow to shareholders[53, 114, 119]

AFM24 (EGFR) + atezolizumab in NSCLC - In EGFRwt NSCLC, the Disease Control Rate (DCR) was 76% (25/33 patients), with 48% (16/33) showing tumor shrinkage and an Objective Response Rate (ORR) of 21% (1 CR, 6 PRs)[16] - In EGFRmut NSCLC, the DCR was 71%, with 41% (7/17) showing tumor shrinkage and an ORR of 24% (1 CR, 3 PRs)[16] - Preliminary median Progression-Free Survival (PFS) in EGFRwt NSCLC was 5.6 months, with 36% of patients ongoing[33, 49] - Patients without prior taxane exposure in EGFRwt NSCLC showed a 25% ORR and a preliminary median PFS of 74 months[47, 53] - Post-hoc analysis showed increasing AFM24 exposure resulted in higher ORR, with the highest exposure group (Q4) achieving a 5455% ORR and a 9091% DCR[68] Acimtamig (AFM13) + AlloNK® in r/r HL - In relapsed/refractory Hodgkin Lymphoma (r/r HL), the ORR was 864% (19/22 patients), including a 545% Complete Response (CR) rate[16, 91] - All patients in the LuminICE-203 study were refractory to brentuximab vedotin (BV) and checkpoint inhibitors (CPIs)[80] AFM28 in r/r AML - In the highest dose level (300 mg), a composite complete remission rate (CRcR) of 40% (4/10 patients) was achieved in relapsed/refractory Acute Myeloid Leukemia (r/r AML)[16, 107]

Financial Performance - Q3 FY25 - Revenue for Q3 FY25 was $67.1 million, within the guided range of $67 million to $71 million[9] - Adjusted EBITDA for Q3 FY25 was $7.3 million, beating the constant currency guidance by $0.3 million[9] - Q3 FY25 Adjusted EBITDA was $7.3 million, a decrease of 47.5% compared to $13.9 million in Q3 FY24[15, 27] - Q3 FY25 revenue was $67.1 million, a decrease of 8.5% compared to $73.4 million in Q3 FY24[15, 27] Financial Performance - YTD Q3 FY25 - Revenue for YTD Q3 FY25 was $195.8 million, a decrease of 3.6% compared to $203.1 million in YTD Q3 FY24[15, 27] - Adjusted EBITDA for YTD Q3 FY25 was $17.0 million, a decrease of 47.3% compared to $32.3 million in YTD Q3 FY24[15, 27] - YTD Q3 FY25 Free Cash Flows were $10.6 million, compared to $30.6 million in Q3 FY24 YTD[15] Guidance Update for FY25 - Updated revenue guidance for FY25 is $265 million to $275 million, a decrease of $10 million from the previous guidance[9] - EBITDA guidance for FY25 is $28 million to $33 million, a decrease of $2 million at the low end from the previous guidance[9] Enterprise Division - North America - Billed Deferred subscription Revenue Balance was $45.0 million, compared to $47.2 million in Q3 FY24[16] - Subscription Revenue was $20.9 million, compared to $22.0 million in Q3 FY24[16] - Revenue was $37.1 million, compared to $40.6 million in Q3 FY24[16] - Unbilled Deferred Revenue Balance was $56.4 million, compared to $64.4 million in Q3 FY24[16] - Subscription & Subscription Services Revenue was $33.7 million, compared to $35.9 million in Q3 FY24[16] Education Division - Invoiced Amounts were $15.0 million, compared to $19.0 million in Q3 FY24[23] - Subscription & Subscription Service Revenue was $17.8 million, compared to $18.2 million in Q3 FY24[23] - Revenue was $18.6 million, compared to $20.2 million in Q3 FY24[23] - Deferred Subscription Revenue Balance was $34.1 million, compared to $28.2 million in Q3 FY24[23] - Subscription revenue increased 13% and Deferred Revenue balance grew 21% in Q3[14]

Gedatolisib: A Novel PAM Inhibitor - Gedatolisib, a pan-PI3K/mTOR inhibitor, shows potential as a highly potent and cytotoxic agent with a differentiated mechanism of action and pharmacokinetic profile[7, 23] - Gedatolisib has demonstrated compelling preliminary results in HR+/HER2- advanced breast cancer (ABC) patients, with a median progression-free survival (mPFS) of 48 months in 1st line and 12.9 months in 2nd line settings[7, 23] - Gedatolisib is more potent against each node than other PAM inhibitors, with >300X higher potency and 1.5x – 2.8x higher cytotoxicity than other PAM inhibitors in vitro[30] - Gedatolisib has a lower rate of Grade 3/4 hyperglycemia (>95% lower) and treatment-related discontinuations (>80% lower) compared to approved PI3K inhibitors[31] Clinical Development and Market Opportunity - Celcuity is conducting a Phase 3 study in 2nd line HR+/HER2- ABC patients and expects to begin enrolling a Phase 3 study in 1st line patients in Q2 2025[7, 158] - The PAM pathway is the most frequently altered pathway in solid tumors (38%), yet drug revenues from PAM inhibitors are a small fraction of other targeted therapy classes[10, 18] - The potential patient population for PAM inhibitors in breast and prostate cancers is estimated to be >500,000 in the US, EU5, and Japan[10] - US market opportunity for Gedatolisib in HR+/HER2- Breast Cancer and Advanced Prostate Cancer is estimated at ~$5-$6 Billion for 2L ABC Post-CDKi + AI, ~$10B+ for 1L ABC ET Sensitive, ~$3B for 1L ABC ET Resistant, $6-$8B for High Risk EBC Adjuvant, $8B+ for 1L/2L mCRPC Post-ARi, $10B+ for 1L mCRPC, $6-$8B for nmCRPC, $10B+ for mHSPC[52] Financial Position - Celcuity has cash, cash equivalents, and short-term investments of $205 million as of Q1 2025, expected to fund operations through 2026[8, 159]